RPC's Q3 Adjusted Earnings, Revenue Rise-February 2024-www.financetom.com

RPC's Q3 Adjusted Earnings, Revenue Rise

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

RPC's Q3 Adjusted Earnings, Revenue Rise

Nov 2, 2024 7:42 PM

08:21 AM EDT, 10/24/2024 (MT Newswires) -- RPC (RES) reported Q3 adjusted earnings Thursday of $0.09 per diluted share, up from $0.08 a year earlier.

Analysts polled by Capital IQ expected $0.13.

Revenue for the quarter ended Sept. 30 was $337.7 million, up from $330.4 million a year earlier.

Four analysts surveyed by Capital IQ expected $368.9 million.

The company said its board maintained its quarterly dividend at $0.04 per share, payable Dec. 10 to shareholders as of Nov. 11.

RPC's shares fell 2.2% in recent Thursday premarket activity.

Price: 6.15, Change: -0.14, Percent Change: -2.23

Previous page： Nike Bets On Olympics to Boost Performance Sales: Report Next page： Polestar Q1 Volume Declines From Previous Quarter

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Nike Bets On Olympics to Boost Performance Sales: Report

Apr 11, 2024

Nike ( NKE ), Inc. shares are trading higher today. The company reportedly launched Olympic kits for the teams it sponsors and athletes. The company roped in athletes such as Kenyan marathon star Eliud Kipchoge and British sprinter Dina Asher-Smith, betting that top athletes can help it win more everyday consumers, reported Reuters. As per the report, this summer’s Olympic Games...

Polestar Q1 Volume Declines From Previous Quarter

Apr 11, 2024

09:45 AM EDT, 04/11/2024 (MT Newswires) -- Polestar (PSNY) said Thursday that it delivered approximately 7,200 cars in Q1, down from 12,800 cars the previous quarter. 2024 is a transitional year, as we move from being a one-car brand during the first half of the year, to ramping up deliveries of our two luxury SUVs during the second half, Chief...

Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints

Apr 11, 2024

09:46 AM EDT, 04/11/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) unit Teva Pharmaceuticals said Thursday that a late-stage trial in China assessing the efficacy and safety of Ajovy to prevent migraine in adults achieved the primary endpoint and all secondary endpoints. The company said the drug significantly decreased the number of migraine days seen per month and...

Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug

Apr 11, 2024

09:46 AM EDT, 04/11/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) shares jumped 27.5% in recent trading Thursday after the company said its potential treatment for pancreatic cancer CAN-2409 has received orphan drug designation from the US Food and Drug Administration. Recently reported data from a phase 2 clinical trial showed that when added to standard of care, CAN-2409...